Michael Dickinson

Dr. Michael Dickinson, a medical professional specializing in lymphomas, discusses the potential of bispecific antibodies in the clinical management of lymphoma, including their mechanism of action and side effects. He explores the challenges of treating relapse after CAR T cell therapy and the advantages of using biospecific antibodies in patients who have not responded to CAR T cell therapy. The podcast also delves into the toxicity management of bispecific antibodies and the complexities of funding and outpatient treatments for refractory lymphoma. Finally, it explores the difficulties in eliminating chemotherapy from lymphoma treatments and the challenges in running trials for chemo ineligible patients.

Experts Michael Dickinson and Tycel Phillips discuss updates in non-Hodgkin lymphoma at ASH 2022, including the TRIANGLE trial, the changing role of transplantation, and novel immunotherapies in the field.